Common questions about Korlym (FAQ)
Q: Why is Korlym part of a special program for access?
A: Korlym is not part of the Risk Evaluation and Mitigation Strategy (REMS) program when used for Cushing’s syndrome. However, the mifepristone component of Korlym is part of a restricted distribution program when used for other indications, and official regulatory review ensured this program’s safety requirements were maintained.
Q: How long does it typically take to see any effect from Korlym?
A: According to official product information, it may take approximately six weeks or longer to observe the full intended benefit of Korlym. The medication works by blocking cortisol receptors, and it takes time for the body's systems to functionally shift away from the effects of high cortisol.
Q: Can Korlym interact with common over-the-counter pain relievers?
A: Regulatory documents indicate that Korlym is a strong inhibitor of several liver enzymes, meaning it can cause the concentrations of certain co-administered medicines to increase in the bloodstream. Regulatory warnings indicate the need for caution with medicines that are metabolized by the CYP3A, 2C8, or 2C9 enzymes, including some over-the-counter pain relievers. Korlym may also increase the risk of QTc prolongation (an effect on heart rhythm) when combined with certain drugs.
Q: Does Korlym affect my ability to drive or operate machinery?
A: Common side effects of Korlym include dizziness, headache, and fatigue or tiredness. Due to these reported effects, caution is advised when performing tasks that require full mental alertness, such as driving or operating machinery.
Q: Are there any long-term effects of taking Korlym?
A: Korlym is intended for long-term use as Cushing’s syndrome is a chronic condition that requires ongoing management. Official information indicates that continued, long-term use requires monitoring for potential risks, including changes to the uterine lining (vaginal bleeding), eye problems (retinopathy), and major adverse cardiovascular events.
Q: Why do official materials mention a Risk Evaluation and Mitigation Strategy (REMS) for Korlym?
A: The FDA’s review of Korlym for Cushing’s syndrome determined that a specific REMS program was not necessary for this product. However, the manufacturer is still required to maintain the safety program for the related pregnancy termination product containing mifepristone, which is due to the drug’s pharmacological effects.
Q: Can Korlym affect my sleep patterns?
A: Official reports of side effects include fatigue and trouble sleeping (insomnia). These effects can interfere with a patient’s usual sleep patterns. If these effects persist or are concerning, regulatory guidance suggests consulting a healthcare provider.
Q: Why is Korlym not recommended for use during breastfeeding?
A: Studies confirm that the active ingredient, mifepristone, is present in human milk. There is currently no data to confirm what effects this may have on a breastfed infant. Official regulatory information advises that the choice to continue the drug or breastfeeding involves a discussion with a healthcare provider, weighing the potential effects on the infant.
Q: Can Korlym cause skin changes or bruising?
A: Some skin-related effects have been reported, including skin rashes and pruritus (itching). It should be noted that many patients with Cushing’s syndrome experience skin changes and bruising as part of their underlying condition.
Q: Is Korlym an older or newer medication?
A: Korlym (mifepristone) was approved by the U.S. Food and Drug Administration (FDA) in 2012.
Q: What should I do if I think I'm having a serious side effect from Korlym?
A: If you experience any concerning or serious symptoms, such as an irregular menstrual period or potential signs of adrenal insufficiency (a serious complication), contacting a healthcare provider immediately is advised, as these may be signs of adrenal insufficiency.
Q: Does Korlym affect fertility?
A: In women of reproductive age, the medication may make it harder to become pregnant during treatment. Because of the risk to an unborn child, women must use a non-hormonal, medically acceptable form of contraception during treatment and for a period following the last dose, as specified in the prescribing information. Studies have not been done to evaluate the effects on male fertility.
Q: Do I need to carry any special card or documentation while taking Korlym?
A: Official information directs patients to receive and keep the manufacturer's Patient Information Sheet (Medication Guide) when beginning and refilling the prescription. This document contains key information about the drug's use and safety.
Q: How often do I need to see my doctor while on Korlym?
A: The initial dosing process is slow, as the dose is adjusted based on how well you tolerate the medicine. Dose adjustments are made not more often than once every two to four weeks, meaning regular contact and visits with your doctor are required during this titration period.
Q: Does Korlym change the appearance of the typical Cushing's symptoms?
A: Clinical trials focused on metabolic and physical outcomes and found that participants experienced a statistically significant reduction in body weight and waist circumference. These changes often contribute to the visible effects of Cushing's syndrome.
Q: Are there any warnings about Korlym and glaucoma?
A: While not directly listed as an adverse reaction, the FDA has required postmarketing analysis of long-term risks, which includes the potential for retinopathy (damage to the back of the eye). Any change in vision should be discussed with your healthcare provider.
Q: What is the experience of people who have been on Korlym for several years?
A: Korlym is intended for the management of a chronic condition. The FDA has required postmarketing studies to continue collecting data on serious adverse events associated with long-term exposure to the therapy, allowing for continuous safety assessment beyond the initial clinical trials.
Q: How is the need for continued Korlym treatment assessed?
A: A healthcare provider assesses the ongoing need for Korlym treatment by evaluating a patient’s clinical tolerability and the degree of improvement in the specific signs and symptoms of Cushing's syndrome.
Q: Does Korlym cure Cushing's syndrome, or just manage symptoms?
A: The official indicated use of Korlym is for the control of hyperglycemia (high blood sugar) that results from hypercortisolism in patients with Cushing's syndrome. This function, along with the improvements seen in clinical studies, indicates that the medicine is used to manage the effects and symptoms of the condition.
Q: Can Korlym cause changes in mood or behavior?
A: Clinical trials found that a significant number of participants experienced improvement in depression symptoms. However, due to the nature of the underlying condition, it is generally recommended to monitor mental health closely, as psychiatric effects can occur in patients with Cushing's syndrome. Changes in a pre-existing mental health condition should be discussed with a healthcare provider.
Q: Are there any specific foods or drinks to avoid while taking Korlym?
A: The consumption of grapefruit or grapefruit juice is officially restricted because it can increase the amount of Korlym that gets into your bloodstream, raising the risk of side effects. If there are concerns about other foods or beverages, a healthcare provider can provide guidance.
Q: Do I need to get regular blood tests while on Korlym?
A: Yes, regulatory documents mandate the monitoring of serum potassium levels due to the potential risk of low potassium (hypokalemia), which is a common adverse reaction. Your healthcare provider will determine if other regular blood tests are necessary based on your overall condition and other medications.
Q: Can Korlym cause weight gain or loss?
A: In clinical trials, Korlym was shown to result in a statistically significant reduction in both body weight and waist circumference in participants. Weight gain is not reported as a common adverse reaction in official product information, but weight loss was observed as an efficacy outcome.
Q: Is Korlym safe to use if I have a history of liver problems?
A: Official information states that the medicine is not recommended for patients with severe hepatic impairment (severe liver problems). Additionally, a lower maximum dose is mandated for patients with mild-to-moderate hepatic impairment. It is important that any history of liver problems is fully disclosed to the healthcare team.
Q: How long can a person stay on Korlym treatment?
A: Korlym is officially intended for long-term use. There is no predetermined time limit on treatment, as the duration is based on the patient's ongoing clinical needs and the decision of their healthcare provider.
Q: What are the possible signs of having too much or too little cortisol while on Korlym?
A: The most important safety concern is the risk of adrenal insufficiency, which is the clinical state of having too little functional cortisol. If you experience signs such as unusual fatigue, severe weakness, nausea, or vomiting, contacting a healthcare provider immediately is advised, as these may be signs of adrenal insufficiency.
Q: Do people with Type 2 diabetes need special monitoring while on Korlym?
A: Yes, Korlym is approved specifically for patients with Cushing’s syndrome who have Type 2 diabetes or glucose intolerance. The interaction profile warns of an increased risk of hypoglycemia (low blood sugar) when Korlym is used alongside antidiabetic agents. Patients with diabetes may require close monitoring of their blood sugar due to this interaction.
Q: Is it normal to feel tired when first starting Korlym?
A: Yes, fatigue or tiredness is listed as a very common or common adverse reaction in the official safety profile. Effects like this are generally more pronounced when a patient first begins treatment or when the dose is being adjusted.
Q: How does Korlym interact with other prescription medications for blood pressure?
A: Korlym is known to cause hypertension (high blood pressure) as a common side effect and can affect certain heart rhythms. It is an enzyme inhibitor, meaning it can increase the concentration of many other medicines, including those used for blood pressure. Your provider should carefully review all your current medications.
Q: Does Korlym interact with herbal supplements like St. John's Wort?
A: The official prescribing information contraindicates the co-administration of Korlym with strong CYP3A inducers because they can dangerously lower the concentration of Korlym. Certain herbal supplements, such as St. John's Wort, are known to be strong CYP3A inducers, and their use is strongly discouraged in regulatory information.
Q: Is Korlym effective for Cushing's syndrome caused by adrenal tumors?
A: Korlym is approved for adult patients with endogenous Cushing's syndrome caused by hypercortisolism, and the approval does not distinguish effectiveness based on the source of the cortisol overproduction (e.g., pituitary or adrenal). The approval criteria focus on the resulting clinical condition (hypercortisolism with diabetes/glucose intolerance).
Q: Can Korlym make existing mental health conditions worse?
A: Clinical trials found that a significant number of participants experienced improvement in depression symptoms. However, due to the nature of the underlying condition, it is generally recommended to monitor mental health closely, as psychiatric effects can occur in patients with Cushing's syndrome. Changes in a pre-existing mental health condition should be discussed with a healthcare provider.
Q: Does the evidence for Korlym come from large clinical trials?
A: The initial approval was based on a pivotal study that included 50 adults, and subsequent research has been conducted through randomized, double-blind, placebo-controlled studies. The evidence is sourced from multiple statistically significant clinical trials that meet regulatory standards for safety and efficacy assessment.
Q: Can Korlym be used if I have kidney disease?
A: If you have severe renal impairment (severe kidney disease), the maximum allowed dose is restricted and must be lowered. It is necessary to inform the healthcare provider of the full history of kidney disease to ensure appropriate dosage constraints are applied.
